Listen to Gynecologic Oncology cover art

All Episodes

Listen to Gynecologic Oncology — 72 episodes

#
Title
1

FIGO 2023 Upstaging: Overtreatment or Overdue Precision?

2

ERAS 2026: Key Updates Every Gynecologic Oncologist Should Know

3

Beyond the Binary: Unpacking Molecular Diversity in PMMR Endometrial Cancer

4

Cologuard-like test for identification of endometrial cancer through vaginal sampling

5

PARP Inhibitors in Ovarian Cancer: A Society of Gynecologic Oncology Podcast

6

Home the Same Day? Testing the Limits in Ovarian Cancer Debulking Surgery

7

Recognizing and Managing ADC-Associated Pulmonary Toxicities

8

In good SHAPE

9

ctDNA-Guided PARPi Therapy in Ovarian Cancer

10

Beyond treatment: The who, why, when, where and what of cancer follow up

11

Ovarian Cancer After Breast Cancer in Women with BRCA Variants

12

Making a difference: Molecules, mechanisms and more

13

Navigating Surgical Complexity After Ovarian Cancer Neoadjuvant Chemotherapy

14

Cervical Cancer Care in Focus: Consensus on Quality, Equity, and Radiation Therapy

15

Beyond Anesthesia: Self-Hypnosis in ERAS Programs

16

Carcinosarcoma Wars: A New Hope for TROP-2 Therapeutic Targeting

17

To divert or not to divert: that is the question

18

A randomized clinical trial of metformin in endometrial cancer

19

Understanding the Implications of the Platinum-Free Interval in Endometrial Cancer

20

Prophylactic chemotherapy to prevent post-molar gestational trophoblastic disease - a long journey and a remarkable study

21

Clinical trials: Panacea or pitfall

22

FOLR1 status: Landscape beyond high grade serous ovarian cancer

23

Benefits of hormonal therapy for low grade serous ovarian cancer

24

Implementation and impact of a financial navigation program in gynecologic oncology

25

LVSI in Stage 1 Endometrial Cancer

26

Primary Surgery versus Radiotherapy for Inguinal Lymph Nodes in Vulvar Cancer

27

2023 FIGO staging for endometrial cancer: a reappraisal on the path to continuous improvement

28

Shifting trends and sicker patients - the future of gynecologic cancer

29

SENTIREC-endo study: Is the juice worth the squeeze?

30

Caring for the Caregiver

31

Lunchbox Trial

32

Optimization of endometrial cancer survivorship through modification of lifestyle factors

33

Engagement with ERAS patients leads to improved outcomes

34

OS updates for Imagyn50

35

Is now the time to begin thromboprophylaxis for all patients with advanced ovarian cancer, including those undergoing neoadjuvant chemotherapy?

36

What is your center doing to improve genetic testing following abnormal MMR results in endometrial cancer?

37

The evolution of patient-centered endometrial cancer detection: testing tompon-based collection for methylated DNA markers

38

TKI Toxicities: A Society of Gynecologic Oncology Podcast

39

ERAS Society Updates: What Every Gyn Oncologist Should Know

40

Prioritizing and achieving diversity in clinical trial enrollment

41

The times they are a changin’ – the future of the specialty

42

Intrathoracic Surgery and Ovarian Cancer Cytoreduction: Why the Chest Matters

43

A Geo-Analyzer Tool that assessed insured patients in your metropolitan area with recurrent and metastatic cervix cancer

44

Molecular Testing for Endometrial Cancer: A Society of Gynecologic Oncology Podcast

45

Sentinel lymph node mapping in endometrial complex atypical hyperplasia: good idea or have we gone too far?

46

Burnout and gynecologic oncology - does the problem still exist?

47

Exceptional PARP inhibitor responders: the good and the bad

48

Management of primary low-grade serous ovarian carcinoma: are you up-to-date on the most contemporary prognostic factors and treatment strategies?

49

How do you manage the contralateral groin in early stage vulvar cancer with a unilateral positive sentinel lymph node?

50

Frailty assessment in gynecologic oncology - have you incorporated this into your practice?

51

Complications after cytoreductive surgery and its impact on survival: where do we go from here?

52

Immunotherapy Toxicities: A Society of Gynecologic Oncology Podcast

53

Long-term cardiovascular complications among gynecologic cancer survivors

54

Financial toxicity – the other side effect of cancer care

55

Reducing non-surgical readmissions in gynecologic oncology

56

Improving QOL for patients with cervical cancer: SLN biopsy

57

The ProMisE of molecular classification to standardize care in endometrial cancer

58

HRD: What does it really mean and are we looking at this the right way?

59

Optimizing Rural Ovarian Cancer Care

60

Recurrent Endometrial Cancer: A Society of Gynecologic Oncology Podcast

61

Looking Back at 2021: November Editor’s Choice

62

Differences in cervical cancer screening and follow-up for black and white women in the United States

63

March 2021: The Future Of Gynecologic Oncology: We are at a Crossroads

64

April 2020: Rare Tumors and Conditions

65

2020 Virtual Annual SGO Meeting Report

66

PARP Inhibitor Maintenance Therapy after Initial Chemotherapy for Advanced Ovary, Fallopian Tube and Primary Peritoneal Cancers

67

Present and Future Impact of COVID-19 on the Practice and Delivery on Gynecologic Oncology Care

68

Financial hardship among gynecologic cancer patients

69

Does the transcriptome of ovarian neoplasms provide insight into its potential behavior?

70

December 2019 Editor's Choice

71

Survival of endometrial cancer patients following lymphadenectomy or sentinel node procedure

72

Inaugural Gynecologic Oncology Podcast - When to stop hCG surveillance following chemotherapy for gastational trophoblastic neoplasia